Asia FX steady as Fed, BOJ rate decisions loom; US-China talks in focus
Stephen Sherwin, a director at Biogen Inc. (NASDAQ:BIIB), recently sold 8,760 shares of the company’s common stock. The transaction, which took place on March 7, 2025, involved shares sold at an average price of $150.0162 each, totaling approximately $1.31 million. The sale occurred with the stock trading near its 52-week low of $128.51, though InvestingPro analysis indicates the company is currently undervalued. Following this sale, Sherwin retains ownership of 11,318 shares in the biotechnology company. This transaction was reported in a filing with the Securities and Exchange Commission. The $22 billion market cap company maintains strong fundamentals with a P/E ratio of 13.65 and robust free cash flow yield. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report about Biogen’s financial health and growth prospects.
In other recent news, Biogen has entered a strategic collaboration with Stoke Therapeutics (NASDAQ:STOK) to develop and commercialize zorevunersen, a potential treatment for Dravet syndrome, outside North America. This partnership is set to enhance Biogen’s rare disease pipeline, with Biogen securing exclusive commercialization rights for territories outside the U.S., Canada, and Mexico. The Phase 3 EMPEROR study for this treatment is scheduled to commence in mid-2025. Meanwhile, Biogen’s recent earnings report has led several analyst firms to adjust their price targets and ratings. Oppenheimer has maintained an Outperform rating with a $255 target, highlighting the strategic fit of the Stoke collaboration. Piper Sandler, however, has reduced its price target to $135, maintaining a Neutral rating due to concerns over declining revenue forecasts. Similarly, Bernstein SocGen has adjusted its price target to $159, citing a cautious outlook for Biogen’s multiple sclerosis treatments. TD Cowen has lowered its target to $200 but kept a Buy rating, noting the company’s revenue challenges and undervaluation of its stock. These developments underscore the mixed analyst sentiment surrounding Biogen’s financial prospects and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.